{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Soligenix, Inc. technically bullish or bearish?
As of April 7, 2025, Soligenix, Inc. exhibits a mildly bearish trend, with mixed signals from key indicators like a mildly bullish MACD and KST, but bearish Bollinger Bands and moving averages, suggesting a cautious outlook.
Is Soligenix, Inc. overvalued or undervalued?
As of August 13, 2021, Soligenix, Inc. is considered overvalued at $1.65 due to its negative P/E ratio, high Price to Book Value of 1.74, and unsustainable ROCE of 295.01%, especially when compared to peers with worse EV to EBITDA ratios.
Who are in the management team of Soligenix, Inc.?
As of March 2022, the management team of Soligenix, Inc. includes Dr. Christopher Schaber as Chairman, President, and CEO, along with independent directors Mr. Gregg Lapointe, Ms. Diane Parks, Dr. Robert Rubin, and Dr. Jerome Zeldis.
What does Soligenix, Inc. do?
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing treatments for rare diseases, with a market cap of $5.88 million and a recent net profit of -$3 million. The company has no dividend yield and is currently loss-making.
How big is Soligenix, Inc.?
As of Jun 18, Soligenix, Inc. has a market capitalization of 5.88 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -9.59 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
